Cantor Fitzgerald Boosts Earnings Estimates for Pharvaris

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share estimate for Pharvaris to ($2.87) from a previous forecast of ($3.41). They maintain an "Overweight" rating with a price target of $25.00.
• Pharvaris reported a quarterly earnings result of ($0.94) EPS, missing expectations by ($0.07).
• Five investment analysts currently rate Pharvaris with a "buy" recommendation, leading to an average target price of $35.60 for the stock.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Pharvaris in a research note issued on Wednesday, August 13th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will earn ($2.87) per share for the year, up from their prior forecast of ($3.41). Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. Cantor Fitzgerald also issued estimates for Pharvaris' FY2026 earnings at ($2.72) EPS.

Several other analysts have also commented on PHVS. Zacks Research upgraded Pharvaris from a "strong sell" rating to a "hold" rating in a report on Monday. Wedbush reiterated an "outperform" rating and set a $27.00 price objective on shares of Pharvaris in a report on Thursday, June 5th. JMP Securities decreased their price objective on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a report on Wednesday, August 13th. Finally, Guggenheim assumed coverage on Pharvaris in a report on Wednesday, June 11th. They set a "buy" rating and a $32.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.60.

Pharvaris Stock Performance

Pharvaris stock traded down $0.26 during mid-day trading on Friday, reaching $23.00. 96,835 shares of the company were exchanged, compared to its average volume of 79,925. The business has a fifty day moving average of $19.90 and a 200 day moving average of $17.31. The firm has a market cap of $1.20 billion, a P/E ratio of -6.85 and a beta of -2.81. Pharvaris has a 12-month low of $11.51 and a 12-month high of $26.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07).

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Soleus Capital Management L.P. lifted its position in Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after acquiring an additional 216,483 shares during the period. Octagon Capital Advisors LP lifted its position in Pharvaris by 25.4% during the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after acquiring an additional 157,530 shares during the period. Rock Springs Capital Management LP lifted its position in Pharvaris by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock worth $14,859,000 after acquiring an additional 18,200 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after acquiring an additional 118,408 shares during the period. Finally, TFG Asset Management GP Ltd lifted its position in Pharvaris by 48.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company's stock worth $3,311,000 after acquiring an additional 61,105 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.